Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of C16 polypeptide and angiogenin Ang1 and drug applying C16 polypeptide and angiogenin Ang1

An angiogenin and drug technology, applied in the field of both application and application of drugs, can solve the problems of complex traditional Chinese medicine ingredients, side effects of viral vectors, and few clinical treatment applications, and achieve the effects of reducing loss and good therapeutic effect.

Inactive Publication Date: 2018-11-27
韩曙
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the ingredients of traditional Chinese medicine are complicated, and the toxic and side effects are difficult to control; gene therapy itself is a double-edged sword, and the use of viral vectors is more likely to cause serious side effects; T cell vaccines and stem cell transplantation are still in the stage of experimental exploration, and there are few clinical applications , and the long-term effect needs to be further observed
Therefore, there is still a lack of economical, safe and long-acting methods for the treatment of infectious and / or non-infectious inflammation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of C16 polypeptide and angiogenin Ang1 and drug applying C16 polypeptide and angiogenin Ang1
  • Application of C16 polypeptide and angiogenin Ang1 and drug applying C16 polypeptide and angiogenin Ang1
  • Application of C16 polypeptide and angiogenin Ang1 and drug applying C16 polypeptide and angiogenin Ang1

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0098] The corresponding animal model of acute course multiple sclerosis (MS) Experimental Allergic Encephalomyelitis (EAE) was made from guinea pig spinal cord homogenate for antigen-sensitized Lewis rats. The clinical condition score was scored under the condition of double-blind test grouping according to the grading scoring method reported by Reynolds et al. (J Neurocyto1, 2002, 31(6-7):523-36). The criteria are as follows: 0 points, no obvious abnormality; 1 point, weak and flaccid tail; 2 points, slow movement, mild ataxia; 3 points, hind limb weakness; 4 points, hind limb paralysis; 5 points, quadriplegia or death.

[0099] In this example, 100% of the established animal models develop symptoms 9-10 days after sensitization, the course of the disease is unidirectional, and the score reaches 4-5 points.

[0100] From the day of sensitization of the test animals, the rats were divided into 5 groups, 40 rats in each group: positive control (Vehicle) group, negative control...

Embodiment 2

[0104] For the test rats in Example 1, at 2 weeks, the condition of local inflammatory cell infiltration was also evaluated.

[0105] The grading criteria for local inflammatory cell infiltration in the EAE model are as follows: 1 point: inflammatory cell infiltration is limited to perivascular; 2 points: mild inflammatory cell infiltration in the cerebrospinal cord parenchyma (1-10 / section); 3 points: cerebrospinal cord parenchyma Moderate inflammatory cell infiltration (11-100 / section); 4 points: severe inflammatory cell infiltration in the brain and spinal cord parenchyma (100+ / section).

[0106] Statistical results such as figure 2 shown. The local inflammatory cell infiltration in the positive control group (Vehicle) was mostly 3-4 points. When Ang1 and C16 polypeptide were used alone, they had a certain anti-inflammatory effect; but when Ang1 and C16 polypeptide were used in combination, the synergistic anti-inflammatory effect was even stronger Significantly, combine...

Embodiment 3

[0108] Neuromyelitis optica (NMO) is a demyelinating disease involving both the optic nerve and the spinal cord. The main feature is optic neuritis leading to blindness, accompanied by myelitis and paralysis caused by inflammatory lesions in the brain. Unlike multiple sclerosis, a classic demyelinating disease of the central nervous system (CNS), neuromyelitis optica has a low proportion in Western countries and is more common in Asian countries. It is accompanied by transverse or ascending myelitis in the days or weeks before or after it, accounting for 22% of all demyelinating diseases in my country, seriously affecting the health of the people. Histologically, the lesion is characterized by the disintegration of perivascular astrocyte foot processes, and the expression of aquaporin 4 (APQ4) and astrocyte acidic protein (GFAP) levels are severely reduced, suggesting that this is a disease related to multiple Sclerosis is an autoimmune disease with a different pathogenesis, s...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of biological medicine and particularly provides application of a C16 polypeptide and an angiogenin Ang1 and a drug applying the C16 polypeptide and the angiogenin Ang1. According to the application of the C16 polypeptide and the angiogenin Ang1, the C16 polypeptide and the angiogenin Ang1 are applied to preparing infectious and / or non-infectious inflammation treating drugs which can be applied to different systems as well as treatment on inflammatory diseases and injuries caused by different diseases; when the parts affected by infectious and / or non-infectious inflammations are nervous system, skin system, motor system, digestive system, respiratory system, urinary system, genital system and / or blood circulation system, the infectious and / or non-infectious inflammation treating drugs can achieve good therapeutic effects and preventing effects. The invention also provides an infectious and / or non-infectious inflammation treating drug. The infectious and / or non-infectious inflammation treating drug comprises the active constituents of the C16 polypeptide and the angiogenin Ang1.

Description

technical field [0001] The present invention relates to the field of biomedicine, in particular to the application of C16 polypeptide and angiogenin Ang1 and the medicine for both applications. Background technique [0002] At present, the main clinical treatment for infectious inflammatory diseases is antibacterial drugs. [0003] Abuse of antibiotics, especially broad-spectrum antibiotics, will lead to imbalance of flora in the body, symptoms such as vomiting and nausea, and aggravate the condition. Antibiotics have many side effects, and antibiotics kill bacteria. Antibiotics can only kill white blood cells without bacteria. Such as leukopenia, it will further reduce the body's disease resistance. Antibiotics stimulate the gastrointestinal mucosa to cause drug-induced gastritis and intestinal flora imbalance. Long-term use of antibiotics, or advanced antibiotics, broad-spectrum or combined use of antibiotics, some non-pathogenic bacteria in the intestinal tract will b...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/18A61K9/08A61K9/19A61K47/26A61P29/00A61K38/10
CPCA61K9/0019A61K9/08A61K9/19A61K38/10A61K38/1891A61K47/26A61P29/00A61K2300/00
Inventor 韩曙
Owner 韩曙
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com